在 silico 解码战略通路 阻断 coptisine 阻止阿尔茨海默氏症的病理: 一个机械的洞察力
Abhideep Roy1, Diwakar Kumar2, Pallab Bhattacharya3
1Department of Life Science and Bioinformatics, Assam University, Silchar, Assam 788011 India.
In silico pharmacology
|December 8, 2025
概括
科普蒂辛显示出作为阿尔茨海默病 (AD) 的多标药物的潜力,通过抑制主要标,如乙胆化酶 (AChE) 和BACE1. 需要进一步的研究来验证其在阿尔茨海默病治疗中的有效性和安全性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 计算化学计算化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是粉样质斑块和神经纤维状结.
- 由乙胆酶 (AChE) 活性驱动的胆功能障碍和粉样β (Aβ) 的积累是关键的病理特征.
- 目前阿尔茨海默病的治疗选择有限,需要探索新的多目标策略.
研究的目的:
- 调查天然类化合物科普蒂辛作为阿尔茨海默氏症多目标治疗剂的潜力.
- 评估科普蒂辛对涉及AD病变发生的五个主要标的抑制作用:ACHE,β-分泌酶 (BACE1),γ-分泌酶,GSK3β和DKK1-LRP6相互作用.
主要方法:
- 使用in-silico分子对接研究来评估coptisine与选定的AD目标的结合亲和力.
- 化学信息学和药物动力学分析进行了对已知抑制剂进行比较分析.
主要成果:
- 科普蒂辛在分子对接模拟中显示出抑制所有五个研究目标 (AChE,BACE1,γ-分泌酶,GSK3β,DKK1-LRP6相互作用) 的能力.
- 药物动力学分析表明,康普提辛具有有利的特性,增强了其作为抗老年药物的潜力.
结论:
- 科普蒂辛成为减轻阿尔茨海默病病理学的有希望的多向药物候选者.
- 需要进一步的临床前和临床研究来证实康普提辛在治疗阿尔茨海默病的安全性和有效性.
关键词:
乙烯基胆化酶是一种粉样蛋白β是什么 粉样蛋白β是什么贝塔-分泌aseasease 的时间.科普提西因 (Coptisine) 是一种药物.马的秘密是什么?糖原合成酶激酶3ββ3β3β3β3β3β3β3β3β3β3β3β3β3β3β3β3β3β3β3β3β3β3β3β3β3β3更多相关视频
11:57Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
468
03:08Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
879
相关概念视频
01:22Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:58Cooperative Allosteric Transitions
8.6K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.6K